Welcome to our dedicated page for Enovis news (Ticker: ENOV), a resource for investors and traders seeking the latest updates and insights on Enovis stock.
Enovis Corporation reports recurring developments as a medical technology company focused on reconstructive surgery, rehabilitation, pain management, physical therapy and musculoskeletal care. Company news centers on financial results, guidance, organic sales trends and segment performance in Reconstructive and Prevention & Recovery, including updates tied to new product introductions and end-market conditions.
Enovis announcements also include conference participation and investor presentation activity, with business commentary on clinically differentiated solutions intended to enhance patient outcomes, restore motion and support surgeons, clinicians and other healthcare professionals.
Enovis Corporation (NYSE:ENOV) has unveiled the new Arsenal Ankle Plating System™, expanding its product line with 37 anatomically designed plates across nine families. This innovative system addresses both tri-malleolar and intra-articular fractures, enhancing the company's offerings in the ankle and foot market. The Arsenal System incorporates advanced technologies such as variable angle locking and multi-lock functionality to improve surgical outcomes. The launch reinforces Enovis' commitment to driving growth through differentiated medical solutions.
Enovis Corporation (NYSE: ENOV) will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 13, 2022. CEO Matt Trerotola and CFO Chris Hix will engage with investors at the event in Rancho Palos Verdes, California. The company, previously known as Colfax Corporation, focuses on innovative medical technology aimed at improving patient outcomes and transforming healthcare workflows.
For more details, visit www.enovis.com.
Enovis Corporation (NYSE: ENOV) reported strong first-quarter 2022 results, with sales of $375 million, a 21% increase year-over-year, and 7% organic growth. Reconstructive sales surged 72% to $131 million, while Prevention and Recovery sales rose 4% to $245 million. Adjusted EBITDA grew 25% to $48 million, with a margin of 12.7%. After spinning off ESAB Corporation, Enovis now has no net leverage. The company maintains its full-year guidance, projecting revenue growth of 10% to 14% and adjusted EPS of $2.20 to $2.40.
Enovis Corporation (NYSE: ENOV), an innovative medical technology company, announced it will release pro forma financial results for Q1 FY2022 on May 10, 2022. A public conference call will follow at 8:00 a.m. Eastern, where company officials will discuss the results. Interested parties can join the call by phone or through a webcast on Enovis’ website. The event aims to provide insights into the company's performance and strategies for growth.